Literature DB >> 14512309

In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone.

Taher Nassar1, Sa'ed Akkawi, Ahuva Shina, Abdullah Haj-Yehia, Khalil Bdeir, Mark Tarshis, Samuel N Heyman, Abd Al-Roof Higazi.   

Abstract

Tissue type plasminogen activator (tPA) is a key enzyme in the fibrinolytic cascade. In this paper we report that tPA contains 2 independent epitopes that exert opposite effects on blood vessel tone. Low concentrations of tPA (1 nM) inhibit the phenylephrine (PE)-induced contraction of isolated aorta rings. In contrast, higher concentrations (20 nM) stimulate the contractile effect of PE. The 2 putative vasoactive epitopes of tPA are regulated by the plasminogen activator inhibitor-1 (PAI-1) and by a PAI-1-derived hexapeptide that binds tPA. TNK-tPA, a tPA variant in which the PAI-1 docking site has been mutated, stimulates PE-induced vasoconstriction at all concentrations used. The stimulatory, but not the inhibitory, effect of tPA on the contraction of isolated aorta rings was abolished by anti-low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor (LRP) antibodies. Administering tPA or TNK-tPA to rats regulates blood pressure and cerebral vascular resistance in a dose-dependent mode. In other in vivo experiments we found that the vasopressor effect of PE is more pronounced in tPA knockout than in wild-type mice. Our findings draw attention to a novel role of tPA and PAI-1 in the regulation of blood vessel tone that may affect the course of ischemic diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512309     DOI: 10.1182/blood-2003-05-1685

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Signaling through LRP1: Protection from atherosclerosis and beyond.

Authors:  Philippe Boucher; Joachim Herz
Journal:  Biochem Pharmacol       Date:  2010-10-30       Impact factor: 5.858

2.  LRP: a bright beacon at the blood-brain barrier.

Authors:  Joachim Herz
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 3.  The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.

Authors:  George W J Harston; Brad A Sutherland; James Kennedy; Alastair M Buchan
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

4.  Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.

Authors:  William M Armstead; John Riley; J Willis Kiessling; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-06-10       Impact factor: 3.619

5.  Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypotension after traumatic brain injury through inhibition of ERK and JNK MAPK.

Authors:  William M Armstead; John Riley; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Neurol Res       Date:  2012-05-30       Impact factor: 2.448

6.  Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.

Authors:  Xiang Fan; Zhanyang Yu; Jianxiang Liu; Ning Liu; Katherine A Hajjar; Karen L Furie; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

7.  tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK.

Authors:  William M Armstead; J Willis Kiessling; John Riley; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Neurol Res       Date:  2011-09       Impact factor: 2.448

Review 8.  Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke.

Authors:  E J Su; L Fredriksson; G P Schielke; U Eriksson; D A Lawrence
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

Review 9.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

10.  uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.

Authors:  William M Armstead; Douglas B Cines; Khalil H Bdeir; Yasmina Bdeir; Sherman C Stein; Abd Al-Roof Higazi
Journal:  J Cereb Blood Flow Metab       Date:  2008-12-03       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.